AU2001263506A1 - Encapsulating a toxic core within a non-toxic region in an oral dosage form - Google Patents

Encapsulating a toxic core within a non-toxic region in an oral dosage form

Info

Publication number
AU2001263506A1
AU2001263506A1 AU2001263506A AU6350601A AU2001263506A1 AU 2001263506 A1 AU2001263506 A1 AU 2001263506A1 AU 2001263506 A AU2001263506 A AU 2001263506A AU 6350601 A AU6350601 A AU 6350601A AU 2001263506 A1 AU2001263506 A1 AU 2001263506A1
Authority
AU
Australia
Prior art keywords
toxic
dosage form
region
potent
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263506A
Other languages
English (en)
Inventor
Michael J. Cima
Christopher M Gaylo
Donald C. Monkhouse
Francis C. Payumo
Jill K. Sherwood
Chen-Chao Wang
Jaedeok Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
AFBS Inc
Original Assignee
Massachusetts Institute of Technology
Therics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Therics Inc filed Critical Massachusetts Institute of Technology
Publication of AU2001263506A1 publication Critical patent/AU2001263506A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001263506A 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form Abandoned AU2001263506A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20589600P 2000-05-18 2000-05-18
US60205896 2000-05-18
PCT/US2001/040763 WO2001087272A2 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form

Publications (1)

Publication Number Publication Date
AU2001263506A1 true AU2001263506A1 (en) 2001-11-26

Family

ID=22764098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263506A Abandoned AU2001263506A1 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form

Country Status (9)

Country Link
US (2) US7276252B2 (enExample)
EP (1) EP1286663B1 (enExample)
JP (2) JP5178982B2 (enExample)
AT (1) ATE315930T1 (enExample)
AU (1) AU2001263506A1 (enExample)
CA (1) CA2408956C (enExample)
DE (1) DE60116758T2 (enExample)
ES (1) ES2257412T3 (enExample)
WO (1) WO2001087272A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
WO2003037244A2 (en) * 2001-10-29 2003-05-08 Therics, Inc. System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
CA2463481A1 (en) * 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
WO2003037607A1 (en) * 2001-10-29 2003-05-08 Therics, Inc. A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form
CA2483028C (en) 2002-05-06 2011-04-05 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050087902A1 (en) * 2003-10-28 2005-04-28 Isaac Farr Alginate-based materials, methods of application thereof, and systems for using the alginate-based materials
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
US7566747B2 (en) * 2004-05-07 2009-07-28 The Board Of Trustees Of The University Of Illinois Wax particles for protection of activators, and multifunctional autonomically healing composite materials
TWI547431B (zh) * 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
JPWO2006004069A1 (ja) * 2004-07-01 2008-04-24 日本碍子株式会社 微小カプセルおよびその製造方法
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
EP1827391B1 (en) * 2004-11-26 2015-09-23 Aprecia Pharmaceuticals Co. Three dimensionally printed dosage forms
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US7612152B2 (en) * 2005-05-06 2009-11-03 The Board Of Trustees Of The University Of Illinois Self-healing polymers
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007082153A2 (en) * 2006-01-05 2007-07-19 The Board Of Trustees Of The University Of Illinois Self-healing coating system
GB0608402D0 (en) * 2006-04-28 2006-06-07 Diurnal Ltd Thyroid treatment
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7569625B2 (en) * 2006-06-02 2009-08-04 The Board Of Trustees Of The University Of Illinois Self-healing elastomer system
JP2009544680A (ja) 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
US20080299391A1 (en) * 2007-05-31 2008-12-04 White Scott R Capsules, methods for making capsules, and self-healing composites including the same
WO2009007969A2 (en) * 2007-07-09 2009-01-15 Colint Ltd. Portable hydration apparatus
US20090181254A1 (en) * 2008-01-15 2009-07-16 The Board Of Trustees Of The University Of Illinois Multi-capsule system and its use for encapsulating active agents
JP2011074015A (ja) * 2009-09-30 2011-04-14 Tomita Pharmaceutical Co Ltd 固形製剤及びその製造方法
DE102010051743B4 (de) 2010-11-19 2022-09-01 C. Miethke Gmbh & Co. Kg Programmierbares Hydrocephalusventil
MY167883A (en) * 2011-05-25 2018-09-26 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices
US8414654B1 (en) * 2011-11-23 2013-04-09 Amendia, Inc. Bone implants and method of manufacture
CN102551927A (zh) * 2011-11-29 2012-07-11 上海大学 嵌入式分级释药三维支架及其制备方法
CN105666875B (zh) 2012-09-05 2017-09-12 阿普雷奇亚制药公司 三维打印系统和设备组件
US8888480B2 (en) 2012-09-05 2014-11-18 Aprecia Pharmaceuticals Company Three-dimensional printing system and equipment assembly
US20140099351A1 (en) 2012-10-04 2014-04-10 Axxia Pharmaceuticals, Llc Process for making controlled release medical implant products
WO2014144661A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Compny Rapidly dispersible dosage form of topiramate
ES2761265T3 (es) * 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación de oxcarbazepina rápidamente dispersable
HK1216513A1 (zh) 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN105579161A (zh) 2013-08-16 2016-05-11 艾克斯温有限责任公司 三维打印的金属铸造模具和其制造方法
EP3057729A4 (en) 2013-10-17 2017-10-18 The Exone Company Three-dimensional printed hot isostatic pressing containers and processes for making same
WO2015100086A1 (en) 2013-12-23 2015-07-02 The Exone Company Methods and systems for three-dimensional printing utilizing multiple binder fluids
WO2015100084A1 (en) 2013-12-23 2015-07-02 The Exone Company Method of three-dimensional printing using a multi-component build powder
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
EP3148730A1 (en) 2014-05-29 2017-04-05 The Exone Company Process for making nickel-based superalloy articles by three-dimensional printing
EP3169499A2 (en) 2014-07-17 2017-05-24 The Exone Company Methods and apparatuses for curing three-dimensional printed articles
US9854828B2 (en) 2014-09-29 2018-01-02 William Langeland Method, system and apparatus for creating 3D-printed edible objects
WO2016089618A1 (en) 2014-12-03 2016-06-09 The Exone Company Process for making densified carbon articles by three dimensional printing
EP4512394A3 (en) 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
CA2996041A1 (en) 2015-08-21 2017-03-02 Aprecia Pharmaceuticals LLC Three-dimensional printing system and equipment assembly
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
CN119925721A (zh) 2016-05-27 2025-05-06 林德拉治疗公司 用于胃驻留系统的材料结构
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
GB201620066D0 (en) * 2016-11-28 2017-01-11 Ucl Business Plc Solid Pharmaceutical dosage formulations and processes
CN110290781A (zh) 2017-01-26 2019-09-27 南京三迭纪医药科技有限公司 胃肠特定部位控制释放的剂型
WO2018156141A1 (en) 2017-02-24 2018-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional (3d) printing a pharmaceutical tablet
GR1009361B (el) 2017-05-11 2018-09-17 Κωνσταντινος Ηλια Θεοδοσοπουλος Συστημα παραγωγης μεσω τρισδιαστατης εκτυπωσης, δισκιων, κοκκιων και καψουλων
EP3635045A1 (en) 2017-05-26 2020-04-15 Infinite Material Solutions, LLC Water soluble polymer compositions
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US10350822B1 (en) 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CN111698983B (zh) 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
DE102018107585B3 (de) * 2018-03-29 2019-03-28 Universität Rostock Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen
IT201800004265A1 (it) 2018-04-06 2019-10-06 Apparato e metodo per la produzione automatizzata di forme di dosaggio personalizzabili.
ES2930199T3 (es) 2018-10-15 2022-12-07 Aprecia Pharmaceuticals LLC Método y sistema para formar una forma farmacéutica dentro de un envase
EP3908244B1 (de) * 2019-01-07 2024-02-07 LuxCan Innovation S.A. Vorrichtung und verfahren für die tablettierung einer pulverförmigen, flüssigen, pastösen, verkapselten oder granularen wirkstoffzusammensetzung
US11724486B2 (en) 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
JP2023533478A (ja) 2020-06-26 2023-08-03 アプレシア・ファーマスーティカルズ・エルエルシー 内部空洞を有する迅速口内分散可能な錠剤
KR20230098628A (ko) 2020-10-30 2023-07-04 트리아스텍 인코포레이티드 위장관 약학적 제형
US12251208B2 (en) 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
GB2608846A (en) * 2021-07-14 2023-01-18 Quay Pharmaceuticals Ltd Method and apparatus for additive manufacturing

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801203A (en) * 1951-03-22 1957-07-30 Byk Gulden Lomberg Chem Fab X-ray method of digestive enzyme diagnosis using protected core of contrast agent
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
WO1994009762A1 (en) * 1992-11-05 1994-05-11 Merck & Co., Inc. Drug delivery device
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
ZA949929B (en) 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ES2283503T3 (es) * 1994-04-22 2007-11-01 Astellas Pharma Inc. Sistema de liberacion de farmaco especifico de colon.
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
WO1998036739A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin

Also Published As

Publication number Publication date
EP1286663A2 (en) 2003-03-05
WO2001087272A3 (en) 2002-04-18
ES2257412T3 (es) 2006-08-01
CA2408956A1 (en) 2001-11-22
EP1286663B1 (en) 2006-01-18
US20060110443A1 (en) 2006-05-25
JP2003533470A (ja) 2003-11-11
JP5178982B2 (ja) 2013-04-10
CA2408956C (en) 2011-07-12
ATE315930T1 (de) 2006-02-15
US7875290B2 (en) 2011-01-25
US7276252B2 (en) 2007-10-02
DE60116758D1 (de) 2006-04-06
DE60116758T2 (de) 2006-11-02
US20020015728A1 (en) 2002-02-07
WO2001087272A2 (en) 2001-11-22
JP2012082224A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
EP1286663B1 (en) Encapsulating a toxic core within a non-toxic region in an oral dosage form
US8728521B2 (en) Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
RU2428176C2 (ru) Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
JP4789806B2 (ja) パントプラゾール多粒子処方
JP2005516020A (ja) ゼロ次持続放出剤形およびその製造方法
JPH0530804B2 (enExample)
PL174178B1 (pl) Preparat farmaceutyczny w postaci kapsułek zawierających kulki
Kaushik et al. Recent patents and patented technology platforms for pharmaceutical taste masking
CZ73196A3 (en) Novel balls for controlled release and pharmaceutical preparation in which said balls are contained
BG65306B1 (bg) Лекарствена форма с контролирано освобождаване, съдържаща галантамин
AU3492201A (en) Timed pulsatile drug delivery systems
JP2003533470A5 (enExample)
KR20090065524A (ko) 프로그래머블 부력전달기술
CN102006862A (zh) 包括弱碱性药物的组合物和控释剂型
IE910852A1 (en) Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
AU2014281702A1 (en) Delayed release cysteamine bead formulation
WO2003053420A1 (en) Multiple-pulse extended release formulations of clindamycin
MX2008016565A (es) Composiciones farmaceuticas que comprenden una combinacion de piperidinoalcanol y descongestivo.
KR20220158703A (ko) 독실아민 석시네이트 및 피리독신 염산염의 변형 방출 다중 단위 경구 제형 및 이의 제조 방법
WO2006045152A1 (en) Improved tabletting process
JP2003137771A (ja) 難溶性薬物用医薬製剤
JP3343144B2 (ja) マイクロカプセル
Fulzele et al. Drug Delivery: Fast Dissolve Systems
CN1935124A (zh) 磷酸川芎嗪缓释微丸及制备方法
AU2005299253A1 (en) Improved tabletting process